Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01940523 · ClinicalTrials.gov registry record · Phase 4
Randomized Controlled Trial of Tranexamic Acid in Total Knee Arthroplasty: Intravenous vs. Topical
A Phase 4 study, sponsored by Hospital for Special Surgery, New York.
- Completed
- Registry status
- Phase 4
- Development phase
- 640
- Enrollment target
NCT01940523 is a Phase 4 study that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 640 participants.
The verdict
NCT01940523, a Phase 4 study, has completed, sponsored by Hospital for Special Surgery, New York.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 640 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether topical or intravenous administration of tranexamic acid during unilateral total knee replacement is more effective at reducing bleeding in the first 24 hours following surgery. Tranexamic acid is a synthetic drug that has been shown to reduce blood drain output and the need for blood transfusions in both its topical and intravenous forms and is commonly used in orthopedic surgery. We hypothesize that IV and topical administration of tranexamic acid will be equally good at reducing the loss of blood and the need for transfusion immediately following total knee replacement.
Interventions
- DRUG Intravenous Tranexamic Acid
- DRUG Topical Tranexamic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 640 participants |
| Start Date | 2013-05 |
| Est. Completion | 2017-05-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01940523
The ClinicalTrials.gov registry entry for NCT01940523 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 640 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intravenous Tranexamic Acid is the first listed.
NCT01940523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01940523 about?
NCT01940523 is a clinical study titled "Randomized Controlled Trial of Tranexamic Acid in Total Knee Arthroplasty: Intravenous vs. Topical". The purpose of this study is to determine whether topical or intravenous administration of tranexamic acid during unilateral total knee replacement is more effective at reducing bleeding in the first 24 hours following surgery. Tranexamic acid is a synthetic drug that has been shown to reduce blood ...
What is the current status of trial NCT01940523?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 640 participants. The study started on 2013-05. Estimated completion is 2017-05-16.
What interventions are being tested in trial NCT01940523?
The interventions under investigation include: Intravenous Tranexamic Acid (DRUG), Topical Tranexamic Acid (DRUG).
Who is sponsoring clinical trial NCT01940523?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.